Monday Mar 11, 2024

استارتاپی برای درمان کشنده ترین سرطان مغز با نصیر مکرم

Exvade Bioscience این اپیزود ما با نصیر مکرم صحبت کردیم. نصیر مدیرعامل استارتاپ

.است

,Exvade تمرکزش بر روی تولید محصولات و روش های نوآوارنه برای درمان سرطان مغزاست. نصیر مدرک دکترای خودش را از دانشگاه  Georgia Tech در رشته ی Materials Science & Engineering گرفته و برای Fellowship  به Stanford رفته. نصیر همچنین دانشیار دانشکده پزشکی  دانشگاه Emory نیز هست.

 

In this episode, we spoke with Nassir Mokarram. Nassir is the CEO of Exvade Bioscience. Exvade focuses on producing innovative products and methods for treating brain cancer. Nassir received his Ph.D. in Materials Science & Engineering from Georgia Tech and went to Stanford for a Fellowship. Nassir is also an Associate Professor at the Emory University School of Medicine.

 

Nassir Mokarram’s Linkedin: https://www.linkedin.com/in/nassir-mokarram-5b966017/

 

Subscribe Secondpod: https://www.youtube.com/channel/UCXmVkqsuJIp5h_sKliUftOw

 

:ویدیو این قسمت را می توانید از طریق لینک زیر مشاهده کنید

https://youtu.be/q853XD67Llo?si=PdsaMXw74JR8-CJ4

منابع 

https://med.emory.edu/directory/profile/?u=NMOKAR2

https://www.youtube.com/watch?v=Uf4usQ26mM4

https://www.youtube.com/watch?v=MM1wNDJn5ac

https://www.amazon.com/Outlive-Longevity-Peter-Attia-MD/dp/0593236599

https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme

https://ufhealth.org/conditions-and-treatments/malignancy#:~:text=The%20term%20%22malignancy%22%20refers%20to,changes%20in%20their%20genetic%20makeup.

https://www.exvadebio.com/team

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030706/

https://docs.google.com/presentation/d/1mXSuVrZbSI_bARq5tfv8UJ9sK2xm6P8E/edit?usp=sharing&ouid=101188950962091710939&rtpof=true&sd=true

 

درباره ی ما

Linkedin: https://www.linkedin.com/company/thes...

Twitter: /thesecondpod  

Instagram: https://www.instagram.com/thesecondpo...

 

#Secondpod #Second_Pod #پادکست ـ دوم

 

Comments (0)

To leave or reply to comments, please download free Podbean or

No Comments

Copyright 2023 All rights reserved.

Podcast Powered By Podbean

Version: 20241125